SCHEMBL7094067

SCHEMBL7094067

CC1Oc2ccc(C(Cc3c(F)cccc3Cl)NC(=O)OC(C)(C)C)cc2NC1=S

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 4/20 0.41
MAPT P10636 3/20 0.41
HTT P42858 3/20 0.41
NPSR1 Q6W5P4 3/20 0.41
MAPK1 P28482 3/20 0.41
HSD17B10 Q99714 3/20 0.41
LMNA P02545 2/20 0.41
MITF O75030 1/20 0.41
SCN9A Q15858 2/20 0.36
CYP3A4 P08684 1/20 0.36
KMT2A Q03164 1/20 0.34
ALDH1A1 P00352 4/20 0.33
TSHR P16473 1/20 0.33
KDM4E B2RXH2 2/20 0.32
RCE1 Q9Y256 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
PPARD Q03181 2/20 0.32
JAK2 O60674 1/20 0.32
TP53 P04637 1/20 0.32
ATM Q13315 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7704807 0.91 HSD17B10 (0.42) HPGDMAPTHTTNPSR1MAPK1
SCHEMBL7087735 0.87 MC4R (0.36) HPGDMAPTHTTNPSR1HSD17B10
SCHEMBL7095873 0.87 CTSS (0.42) HPGDMAPTHTTNPSR1MAPK1
SCHEMBL7090483 0.85 CTSS (0.45) HPGDMAPTHTTNPSR1MAPK1
SCHEMBL7708252 0.85 CTSL (0.45) HPGDMAPTHTTNPSR1MAPK1
SCHEMBL7091267 0.84 HSD17B10 (0.33) HPGDMAPTHTTNPSR1HSD17B10
SCHEMBL7087725 0.83 CTSS (0.41) HPGDMAPTHTTNPSR1MAPK1
SCHEMBL7092472 0.83 HSD17B10 (0.37) HPGDMAPTHTTNPSR1HSD17B10
SCHEMBL7704943 0.83 ALDH1A1 (0.43) HPGDMAPTHTTNPSR1MAPK1
SCHEMBL7093383 0.83 MC4R (0.41) HPGDMAPTHTTNPSR1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1015437-B1 BENZOXAZINE AND BENZOTHIAZINE DERIVATIVES AND THEIR USE IN PHARMACEUTICALS SCHERING AG (DE) 2003-12-03 EP disclosed
US-6365736-B1 TREATMENT OF NERVOUS SYSTEM DISORDERS, CARDIOVASCULAR DISORDERS AND FOR ACTIVITY AS NO-SYNTHASES (NOS) INHIBITORS. SCHERING AKTIENGESELLSCHAFT (DE) 2002-04-02 US disclosed